Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Leukemia 4Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Congenital Abnormalities 3Colonic Neoplasms 3Somatostatinoma 2Recurrence 2Myeloproliferative Disorders 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Islet Cell 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Vipoma 1Uterine Cervical Dysplasia 1Urologic Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocythemia, Essential 1Squamous Intraepithelial Lesions 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Pituitary Neoplasms 1

Interventions

Octreotide 4Everolimus 4Capecitabine 4Temozolomide 3Leucovorin 3vatalanib 2fluorodopa F 18 2Trastuzumab 2Oxaliplatin 2Fluorouracil 2Bortezomib 2Bevacizumab 268Ga-NOTA-exendin-4 2veliparib 1tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1pazopanib 1pasireotide 1motesanib diphosphate 1cixutumumab 1batifiban 1Thalidomide 1Surgical Procedures, Operative 1Streptozocin 1Sorafenib 1Solutions 1Salts 1Saline Solution 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Insulinoma × Biological Therapy × Clear all
NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Withdrawn
Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡